RxDoctor Payments Data

Casey Dillon, PA

Physician Assistant · Crossville, TNNPI 1184175739

Payments from drug & device makers

$895in general payments, 2019–2025

Across 50 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$220
  • AbbVie$216
  • Lilly USA, LLC$216
  • Phathom Pharmaceuticals, Inc.$70
  • Paratek Pharmaceuticals, Inc.$39
  • Abbott$23
  • plus $110 from 7 others

What the payments were for

  • Food & beverage$895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$220
AbbVie11$216
Lilly USA, LLC13$216
Phathom Pharmaceuticals, Inc.4$70
Paratek Pharmaceuticals, Inc.2$39
Abbott1$23
Axsome Therapeutics, Inc.1$20
Cipher Pharmaceuticals US LLC1$17
Halozyme Inc1$16
AstraZeneca1$15
Amgen1$15
Pfizer1$14
GSK1$13

How this compares

$895 in reported general payments places this provider in the 65th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$164,413
Medicare patients
358
Services billed
2,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$121,431
OzempicSemaglutide85$105,211
EliquisApixaban79$75,867
JardianceEmpagliflozin48$61,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$61,271
JanuviaSitagliptin Phosphate23$27,116
Tresiba Flextouch U-200Insulin Degludec35$25,747
FarxigaDapagliflozin Propanediol18$17,286
LinzessLinaclotide23$16,645
RybelsusSemaglutide11$15,827
TrulicityDulaglutide14$13,341
MyrbetriqMirabegron11$8,983
Breo ElliptaFluticasone/Vilanterol12$7,848
Spiriva RespimatTiotropium Bromide12$6,434
Atorvastatin Calcium342$4,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$216$134,77290 claims
Novo NordiskOzempic, Rybelsus$220$121,03896 claims
PfizerEliquis$14$75,86779 claims
GSKTrelegy Ellipta, Breo Ellipta$13$69,11961 claims
AbbVieLinzess, Armour Thyroid$216$18,70752 claims
AstraZenecaFarxiga$15$17,28618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Crossville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →